Premier Endpoint

Unmet Needs

Unmet Needs 2016: Type 2 Diabetes

November 15, 2016 By Stephen Strudwick

Type 2 Diabetes Market Expected to Double by 2025 http://www.pharmpro.com/news/2016/06/type-2-diabetes-market-expected-double-2025 The global type 2 diabetes market is set to almost double from $31.2 billion in 2015 to $58.7 billion by 2025, representing a compound annual growth rate of 6.5%, according to research and consulting firm GlobalData. The company’s latest report states that this growth, which […]

Unmet Needs

Unmet Needs 2016: Atherosclerosis

November 6, 2016 By Stephen Strudwick

Cardiovascular disease is the leading cause of death worldwide. In the U.S., there are approximately 11 million people with atherosclerotic cardiovascular disease (ASCVD) and/or familial hypercholesterolemia (FH) who have uncontrolled levels of low-density lipoprotein (LDL-C) over 70 mg/dL, despite treatment with statins or other cholesterol-lowering therapies. More than 60 percent of high-risk patients in Europe […]

General

Shire Presentations: ASH 2016. Rare Hematologic and Specialty Conditions

November 4, 2016 By Stephen Strudwick

Broad Range of Research to be Presented at ASH 2016 Demonstrates Shire’s Commitment to Addressing Unmet Needs for Patients with Rare Hematologic and Specialty Conditions http://finance.yahoo.com/news/broad-range-research-presented-ash-150000396.html Shire plc (LSE: SHP, NASDAQ: SHPG), the leading global biotechnology company focused on serving individuals with rare diseases, announced today the depth and breadth of the data it will […]

Unmet Needs

Unmet needs 2016: systemic lupus erythematosus

November 3, 2016 By Stephen Strudwick

Five years after approval by the FDA and EMA, IV Benlysta remains the only drug licensed for the treatment of systemic lupus erythematosus (SLE) in almost 60 years, highlighting the difficulty in successfully bringing to market agents to treat this multifactorial disease. Despite the high level of unmet need in SLE, IV Benlysta has seen […]

Oncology

Information needs of oncologists and general practitioners

October 30, 2016 By Stephen Strudwick

Information needs of oncologists, general practitioners and other professionals caring for patients with cancer. https://www.ncbi.nlm.nih.gov/pubmed/27550233 Ciarlo and colleagues recently published the results of a survey focusing on the information needs of oncologists and general practitioners (https://www.ncbi.nlm.nih.gov/pubmed/27550233). Its goals were to identify the specific needs of oncologists and general practitioners attending cancer patients. Survey participants were members of […]

Unmet Needs

Unmet Needs 2016: Myelodysplastic Syndromes (MDS)

October 27, 2016 By Stephen Strudwick

Current State of the Art: Management of Higher Risk Myelodysplastic Syndromes (MDS). Komrokji RS. Clin Lymphoma Myeloma Leuk. 2016 Aug;16 Suppl:S39-43. doi: 10.1016/j.clml.2016.02.019. https://www.ncbi.nlm.nih.gov/pubmed/27521322 Hypomethylating agents are the only medications that alter the natural history of the disease. Azacitidine is the only drug reported to improve overall survival in higher risk MDS patients. Appropriate use […]

Interviews

Nicholas Vogelzang, MD: Unmet Needs in Oncology

October 24, 2016 By Stephen Strudwick

Klara Czobor: Our first question Dr. Vogelzang is what malignancy do you primarily treat in your practice? Dr. Vogelzang: Being a general oncologist in private practice, I get to treat many different malignancies. I primarily treat prostate, kidney, and bladder cancer. I also treat patients with testicular cancer and sarcoma, as well as smaller numbers […]

Unmet Needs

Unmet Needs 2016: Non-Alcoholic SteatoHepatitis (NASH)

October 20, 2016 By Stephen Strudwick

Rising Stars Outlook 2016: New Emergence of Potential Tx & Dx Options could transform the Current Landscape for Liver Diseases (NASH) – Research and Markets http://www.businesswire.com/news/home/20160405005783/en/Rising-Stars-Outlook-2016-Emergence-Potential-Tx Non-Alcoholic SteatoHepatitis (NASH) is an unmet medical need and is becoming the leading cause of liver transplant. No FDA-approved therapies and a meager diagnosis, it poses a unique challenge […]

Unmet Needs

Unmet Needs 2016: Parkinson’s Disease

October 19, 2016 By Stephen Strudwick

New and Emerging Therapies in Parkinson’s Disease As the therapeutic landscape expands, an increasing range of options and a promising horizon will improve management of motor fluctuations for many patients with Parkinson’s disease. By Laxman Bahroo, DO, Fahd Amjad, MD, Khashayar Dhastipour, MD, and Fernando Pagan, MD http://practicalneurology.com/2016/04/new-and-emerging-therapies-in-parkinsons-disease Parkinson’s disease (PD) impairs motor, sensory, autonomic […]

Unmet Needs

Unmet Needs 2016: Inflammatory Bowel Disease

October 17, 2016 By Stephen Strudwick

The Present and Future of Inflammatory Bowel Disease Treatment. William J. Sandborn, MD. Gastroenterol Hepatol (N Y). 2016 Jul; 12(7): 438–441. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4969780/ What are the most significant unmet needs in current inflammatory bowel disease treatment? William J. Sandborn, MD. “With the current biologic drugs, approximately 20% to 35% of patients will achieve remission, and approximately […]